HEALEY Enrolment Complete - Topline Accelerated to Q2 CY27
Filed with ASX · · 2 pages · English
Summary by 6ix AI
This rapid enrolment reflects strong recruitment efforts and operational efficiencies within the trial network, marking a significant milestone for Neurizon's clinical development program. Participants will continue through a planned treatment period, with the company focusing on delivering the study effectively ahead of the results readout.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Neurizon Therapeutics Limited on 6ix
Earlier from Neurizon Therapeutics
- Neurizon executes long-term supply agreement with Elanco
- HEALEY ALS Trial Surpasses 50% Dosing Ahead of Schedule
- HEALEY ALS Platform Trial Regimen I expands to 240 participants
- HEALEY ALS Trial Regimen I Expands to 240 Participants
- Ethics Approval Received for NUZ-001 Oral Liquid P1 Study
Later from Neurizon Therapeutics
- HEALEY ALS Platform Trial Regimen I enrolment completed - Topline results for NUZ-001 accelerated to Q2 CY2027
- Neurizon Enters Strategic R&D Financing Facility
- Appendix 4E and 2026 Annual Report
- Neurizon Appoints Chief Executive Officer
- NIH funds Expanded Access Program for NUZ-001 in ALS
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics